Aurafil Health News https://aurafilhealth.com/pages/news/index.html Physician-led coverage of peptides, FDA regulation, and TRT studies from Aurafil Health. en-us Sat, 25 Jul 2026 00:00:00 -0400 FDA advisory committee recommends 6 of 7 peptides for 503A compounding list — what it means for patients https://aurafilhealth.com/pages/news/2026-07-25-fda-pcac-votes-peptide-compounding.html On July 23–24, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List. Here's what the vote does — and what it doesn't — for patients considering peptide therapy. Sat, 25 Jul 2026 00:00:00 -0400 https://aurafilhealth.com/pages/news/2026-07-25-fda-pcac-votes-peptide-compounding.html Retatrutide clears Phase 3: 22.6% weight loss and a Q1 2027 FDA submission — what this triple agonist means https://aurafilhealth.com/pages/news/2026-07-24-retatrutide-triumph-phase-3-results.html Eli Lilly's first-in-class GLP-1/GIP/glucagon triple agonist delivered up to 22.6% weight loss in patients with severe obesity and cardiovascular disease. Here's what the TRIUMPH-2 and TRIUMPH-3 data show — and why it matters for men on TRT. Fri, 24 Jul 2026 00:00:00 -0400 https://aurafilhealth.com/pages/news/2026-07-24-retatrutide-triumph-phase-3-results.html One year after TRAVERSE: what the landmark cardiovascular safety trial changed in TRT prescribing https://aurafilhealth.com/pages/news/2026-07-21-traverse-trial-one-year-later-trt-cardiovascular-safety.html The 2023 TRAVERSE trial (NEJM) put decades of TRT cardiovascular safety questions to rest — but only if you read what it actually said. Here's what the 5,246-patient RCT concluded, what caveats remain, and how it changed real prescribing. Tue, 21 Jul 2026 00:00:00 -0400 https://aurafilhealth.com/pages/news/2026-07-21-traverse-trial-one-year-later-trt-cardiovascular-safety.html